Skip to main content

NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH) - Get GW Pharmaceuticals Plc Report shares are spiking, up 8.1% to $103.98, on Monday after analysts at Piper Jaffray (PJC) - Get Piper Jaffray Companies Report drastically increased its price target to $147 from $97.

The improved valuation stems from an analyst's evaluation of the U.K. based pharmaceutical company's cannabinoid based epilepsy treatment, Epidolex.

Analysts Dr. Joshua Schimmer believes that the drug is a "highly attractive" treatment for children suffering from Dravet Syndrome, as children treated with it have fewer seizures and can take lower doses of other medicines.

Must Read: Warren Buffett's 25 Favorite Stocks

TheStreet Recommends

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Image placeholder title

GWPH data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.